Faeth Therapeutics

Organisation

Trials

NCT07558733
Phase 1/2, Recruiting, 32 people, 30 Apr 2026
NCT06463028
Phase 2, Recruiting, 40 people, 17 Jun 2024

Named in competing interests

Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer
Consulting or advice, Fees or honoraria, Founder, Board or leadership role, 4 Mar 2026
Anti-uPAR CAR T cells reverse and prevent aging-associated defects in intestinal regeneration and fitness
Consulting or advice, Fees or honoraria, Founder, Board or leadership role, 25 Nov 2025
Reprogramming neuroblastoma by diet-enhanced polyamine depletion
Consulting or advice, Shares or equity, 24 Sept 2025

Sources: pubmed.ncbi.nlm.nih.gov